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This was placebo-controlled double-blind parallel-group comparative clinical trial targeting 80 men and
women aged 50e79 years with halitosis and body and fecal odor. We investigated whether daily
champignon extract ingestion for 4 weeks improved these conditions. Subjects were divided into four
groups: a placebo group and 50, 500, and 1000 mg/day ingestion groups. No severe adverse events or
side effects were noted during the study period. Compared with the placebo group, all champignon
extract ingestion groups showed improvement or tendency toward improvement in halitosis and body
and fecal odor. Furthermore, our results suggested that the effectiveness of champignon extract in
alleviating odors is dose-dependent, i.e., it increases with the dosage.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Kareishu (literally, distinctive body odor of the middle-aged or
elderly), which is believed to frequently occur in men aged 40
years,1 is considered to be more common in modern society
because of high animal fat-containing modern diets and high levels
of stress. Halitosis and body and fecal odor negatively affect peo-
ples' quality of life, and they are increasingly becoming a serious
problem in caregiving settings in Japan, with the rapidly increasing
proportion of the elderly in the Japanese society.
To manufacture champignon extract, an extract boiled from the
mushroom Agaricus bisporus (tsukuritake or champignon mush-
room) is mixed with dextrin and then spray-dried it into a powder.
The extract contains amino acids, polyphenols, polysaccharides,
ﬂavonoids, vitamins, and minerals. Currently, this extract has been
patented and is available for sale in Japan, six European countries,
South Korea, the United States, and Canada. The most signiﬁcant
feature of champignon extract is deodorization within the intesti-
nal tract.
Conditions such as halitosis and body and fecal odor are
believed to be caused by certain toxic substances producedversity, Department of Medi-
do 069-8585, Japan. Fax: þ81
ihira).
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).within the intestinal tract; champignon extract directly inhibits
their production. Thus, champignon extract is widely used in
candy, jellies, drinks, and other food products for maintaining
both personal esthetics and health. Champignon extract shows a
deodorizing effect by inhibiting ammonia nitrogen generation.2
Furthermore, in an in vitro trial using gas chromatography to
investigate its effects on the methyl mercaptan component of
halitosis, champignon extract was found to increase the molec-
ular weight of methyl mercaptan, thereby inhibiting its odor and
causing overall decreased odor. This was because it converts the
mercapto group of methyl mercaptan to sulfo group. Studies
regarding the function of champignon extract and the utility of
its characteristic effects against methyl mercaptan are
underway.2
In a clinical trial targeting elderly inpatients (70 subjects; mean
age: males 73.5 years, females 78.6 years) and involving ingestion
of 2 g of champignon extract daily for 30 days, the extract was
shown to not affect gastrointestinal symptoms but improved stool
characteristics, reduced fecal and body odor, and decreased blood
ammonia content. In another trial involving 24 residents of an
elderly care facility who ingested jelly candies containing 300mg of
champignon extract daily for 30 days, favorable effects such as
improved “stool characteristics” and “life satisfaction” were
observed.
Herewe aimed to investigate whether daily champignon extract
ingestion for 4 weeks improved halitosis and body and fecal odor.rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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2.1. Study design
We included 80 men and women aged 50e79 years with
problematic halitosis and body and fecal odor in this placebo-
controlled double-blind parallel-group comparative study. It
involved four study groups: consisting of 3 test foods and a placebo,
as shown in Table 1. (1) a placebo group (n ¼ 20), (2) 50 mg/day
champignon ingestion group (n ¼ 20), (3) 500 mg/day champignon
ingestion group (n ¼ 20), and (4) 1000 mg/day champignon
ingestion group (n ¼ 20). The ingestion period was 4 weeks. With
regard to ingestion volume and ingestionmethod, the test food was
ingested as one packet (2 g) per day. However, we did not imple-
ment any restrictions regarding method or frequency of ingestion.
The Champignon Extract BX100FPD (Ricom Corporation, Tokyo,
Japan) used for ingestion.
Each subject underwent a medical interview and blood test on
the day of starting ingestion of the test food and after 2 and 4weeks
of ingestion. The week before starting ingestion was set as the pre-
observation period (washout period).2.2. Study procedure
This study was approved by the Bioethics Committee of Hok-
kaido Information University. After providing the subjects with
written and oral explanations of the study contents in accordance
with the Declaration of Helsinki, we obtained written consent to
participate from the subjects. After initially screening, this study
included 80 consenting subjects, who fulﬁlled the selection criteria
and not the exclusion criteria, and were believed to be suitable to
participate by the principal investigator. For group allocation, an
allocation manager from a third-party data center (Media Educa-
tion Center, Hokkaido Institute of Information Technology, Ebetsu,
Hokkaido) referred to the subject list and equally divided the
subjects via stratiﬁed randomization into four groups considering
age composition, male-to-female ratio, and odor questionnaire
scores. The allocation manager carefully stored the allocation-
related documents containing personal information of the sub-
jects in a locked cabinet. Subjects were then notiﬁed of the date,
time, and place for the clinical trial. Because three subjects quit the
study owing to personal reasons before the trial started, only 77
subjects were ﬁnally included.
Subjects ingested one packet (2 g) per day of test food or placebo
for 4 weeks from the day of starting ingestion. Subjects arrived at
the assigned facilities on the day of starting ingestion and after 2
and 4 weeks of ingestion and underwent testing regarding pre-
scribed items. The tests were conducted at the Health Center,
Hokkaido Information University, Ebetsu Internal Medicine Clinic,
Takahashi Internal Medicine 3Ban-dori Clinic, and Taguchi Clinic
(all in Ebetsu, Hokkaido). Subjects began recording information in
their lifestyle journals (daily condition, whether the test food wasTable 1
Composition of placebo and test food materials.
Composition of materials Quantity contained (mg)
Placebo Test food
50 mg/day champign
Champignon extract BX100FPD 0 50
Dextrin 1503.5 1458.1
Glucose 400 400
Malic acid 90 85.5
Caramel (food color) 6.5 6.4ingested, etc.) and also documented their bowel movements 1
week before starting ingestion and then throughout the 4-week
study period until the completion of stool sampling. The journals
were submitted on each clinic day and every time feces were
sampled.
For disclosure (display of allocation list), when all relevant test
results and analysis data had been prepared, the allocation man-
ager displayed the subject allocation list. The ingestion rate was
calculated with the following formula: Ingestion rate
(%) ¼ (number of test foods actually ingested/number of test foods
planned to be ingested)  100.
2.3. Ethics committee
All subjects provided written informed consent before under-
going any study-related tests, and the study protocol was approved
by the Ethics Committee of Hokkaido Information University (a
certiﬁcate number; 2014-04). The study protocol conformed to the
Helsinki Declaration and was registered at the UMIN Clinical Trial
Registration System (certiﬁcate number UMIN000014256).
2.4. Statistical analysis
The Wilcoxon rank sum test was used for intragroup compari-
sons and the ManneWhitney U and chi-square tests were used for
intergroup comparisons.
2.5. Study items
2.5.1. Visual analogue scale (VAS) questionnaire
For VAS questionnaire, 100-mm lines were prepared for each
item with the left and right edges indicating worst and best states,
respectively. We evaluated how subjects felt about their own state
at the time of the questionnaire by having themmark an “X” on the
relevant part of each line. The questionnaire results were scaled by
measuring the length from the left edge to the “X” mark.
Subjects and cooperating people (those living along with the
subjects) were asked to answer the questionnaire regarding hali-
tosis and body and fecal odor using the prescribedmethod. Subjects
were instructed to bathe and brush their teeth the night before and
sleep using a clean pillow cover (or to cover the pillowwith a towel)
while wearing freshly laundered pajamas. The cooperating person
evaluated halitosis after standing one handbreadth away from the
subject and speaking to the subject for 1e2 min. For body odor
evaluation, the odor of the pillow cover (or towel) and pajamas was
evaluated by the subject and cooperating person.
For the questionnaire items regarding bowel movements, sub-
jects evaluated the bowel movement status during the days be-
tween two clinic visits. However, if subjects could not record results
at the time of awakening on the test day, they were allowed to
include results from up to 2 days before the test day. We investi-
gated the following four items: (1) fecal odor, (2) bowel movementon 500 mg/day champignon 1000 mg/day champignon
500 1000.00
1050.1 596.7
400 400
45 0
4.9 3.3
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residual stools. To evaluate fecal odor, the cooperating person
evaluated the smell after the subject used the toilet.
2.5.2. Bowel movement and lifestyle journals
The following characteristics regarding bowel movement were
recorded on a daily basis: (a) bowelmovement frequency, (b) bowel
movement volume (visual estimate of number of sample containers
the stools would ﬁll), (c) stool shape, (d) stool color, (e) stool odor,
and (f) sensation of having completely evacuated after each bowel
movement. The evaluation periods were the 1-week pre-
observation period (non-ingestion period) and 4-week test food
ingestion period. On days when multiple bowel movements were
experienced, subjects recorded items from (b) through (f) for the
ﬁrst bowel movement only. In the lifestyle journal, subjects recor-
ded meal content, physical condition, and whether they ingested
the test food daily.
2.5.3. Physical measurements and blood testing
Blood samples were taken for testing on the starting day and
after 4 weeks of ingestion. In addition to a medical interview by a
doctor, height, weight, bodymass index (BMI), and percent body fat
were measured. Vital signs (blood pressure upon arrival, pulse rate,
body temperature) were also taken. General blood tests included
complete blood count (WBC, RBC, Hgb, Hct, and platelets), liver
function test (AST, ALT, g-GTP, ALP, and LDH), kidney function (BUN,
Cre, and UA), blood lipid proﬁle (total cholesterol, TG, LDL-
cholesterol, and HDL-cholesterol), and blood sugar test (blood
sugar and HbA1c).
2.5.4. Food frequency questionnaire
For the food frequency questionnaire, we used FFQg Ver4
(Kenpakusha, Tokyo, Japan). We used a questionnaire composed of
29 food groups and 10 types based on food classiﬁcations from the
National Health and Nutrition Survey. With 1-week units, we
estimated volume of intake by food group and nutrient intake
based on portion size and food frequency. We calculated mean
values and standard deviation for the intake volume of nutrients
(calories, protein, fat, carbohydrates, dietary ﬁber, and salt) on the
day of starting ingestion and after 4 weeks of ingestion.
3. Results
Table 2 presents the male-to-female ratio, mean age, weight,
BMI, and percent body fat of the four subject groups: placebo group
(n¼ 19), 50 mg/day ingestion group (n¼ 18), 500 mg/day ingestion
group (n ¼ 20), and 1000 mg/day ingestion group (n ¼ 20). For the
continuous variables (age, weight, BMI, and percent body fat), we
performed the Student's t-test with two independent samples. We
used Fisher's exact test to calculate the number and proportion of
male subjects in each group for the categorical variable of sex. WithTable 2
Demographic data for subjects.
Group Placebo 50 mg/day champignon ingestion group 500
Number of subjects n ¼ 19 n ¼ 18 n ¼
Ave. ± SD Ave. ± SD Ave.
Age(years old) 64.4 ± 7.8 64.8 ± 7.3 64.0
Body weight(kg) 60.63 ± 9.95 57.84 ± 9.55 60.1
BMI 23.54 ± 2.72 23.12 ± 2.62 23.1
Body fat (%) 26.93 ± 6.64 25.78 ± 7.37 26.7
Number of male subjects 9 9 11
Proportion of male (%) 47.4 50.0 55.0regard to the analysis groups, no statistically signiﬁcant differences
were observed for ingestion rates between the placebo group and
all ingestion groups (Table 3).3.1. VAS questionnaire for subjects
Mean scores and standard deviation were calculated for each
group for the results of the VAS questionnaire regarding the seven
items of halitosis, pillow odor, pajama odor, fecal odor, bowel
movement regularity, strain during bowel movements, and sensa-
tion of residual stools. We then calculated the amount of change in
mean scores and standard deviation for each group for each mea-
surement time point (evaluation time point) from before starting
ingestion (Table 4). With regard to the amount of change, we also
calculated frequency distribution after dividing these results into
ﬁve levels (<20, 20e39, 40e59, 60e79, and 80 changes expres-
sion in mm). The results for each of these seven items are shown
below.3.1.1. Halitosis
The respective amount of change in VAS questionnaire scores
regarding halitosis from before starting ingestion to after 2 weeks
of ingestion and from before starting ingestion to after 4 weeks of
ingestion was as follows: placebo group, 10.95 ± 16.99 mm and
19.11 ± 18.89 mm; 50 mg/day group, 19.33 ± 20.40 mm and
22.44 ± 22.59 mm; 500 mg/day group, 13.75 ± 17.59 mm and
17.85 ± 20.78 mm; 1000 mg/day group, 20.00 ± 19.22 mm and
29.32 ± 25.56 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, halitosis signiﬁ-
cantly improved after 2 and 4 weeks of ingestion compared with
that before starting ingestion (p ¼ 0.001, p ¼ 0.001). After 2 weeks
of ingestion, differences were also observed between all ingestion
groups and the placebo group. After 4 weeks of ingestion, differ-
ences were observed between the 500 and 1000 mg/day ingestion
groups and the placebo group.3.1.2. Pillow odor
The respective amount of change in VAS questionnaire scores
regarding pillow odor from before starting ingestion to after 2
weeks of ingestion and from before starting ingestion to after 4
weeks of ingestion was as follows: placebo group, 9.00 ± 18.10 mm
and 10.82 ± 22.36 mm; 50 mg/day group, 11.11 ± 10.53 mm and
12.11 ± 17.78 mm; 500 mg/day group, 19.05 ± 22.02 mm and
21.10 ± 26.00 mm; 1000 mg/day group, 12.20 ± 16.47 mm and
17.50 ± 22.99 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, pillow odor
signiﬁcantly improved after 2 and 4 weeks of ingestion compared
with that before starting ingestion (p ¼ 0.004, p ¼ 0.003). After 2
weeks of ingestion, differences were also observed between all
ingestion groups and the placebo group. After 4 weeks of ingestion,mg/day champignon ingestion group 1000 mg/day champignon ingestion group
20 n ¼ 20
± SD Ave. ± SD
± 7.9 63.2 ± 6.8
2 ± 9.03 59.19 ± 11.31
8 ± 2.72 22.83 ± 2.81
8 ± 6.85 27.02 ± 5.14
9
45.0
Table 3
Ingestin rates for placebo and test foods.
Group Placebo 50 mg/day champignon 500 mg/day champignon 1000 mg/day champignon
Number n ¼ 19 n ¼ 18 n ¼ 20 n ¼ 20
Ingestion rate (%) Ave. ± SD Ave. ± SD Ave. ± SD Ave. ± SD
98.31 ± 3.44 99.21 ± 1.96 98.57 ± 3.36 98.57 ± 2.93
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ingestion groups and the placebo group.
3.1.3. Pajama odor
The respective amount of change in VAS questionnaire scores
regarding pajama odor from before starting ingestion to after 2
weeks of ingestion and from before starting ingestion to after 4
weeks of ingestion was as follows: placebo group, 5.05 ± 11.13 mm
and 9.37 ± 17.36 mm; 50 mg/day group, 8.06 ± 13.33 mm and
7.00 ± 17.23 mm; 500 mg/day group, 20.75 ± 22.19 mm and
21.70 ± 28.25 mm; 1000 mg/day group, 12.15 ± 17.33 mm and
15.00 ± 20.48 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, pajama odor
signiﬁcantly improved after 2 and 4 weeks of ingestion compared
with that before starting ingestion (p ¼ 0.005, p ¼ 0.004). After 2
weeks of ingestion, differences were also observed between all
ingestion groups and the placebo group. After 4 weeks of ingestion,
differences were observed between the 500 and 1000 mg/day
ingestion groups and the placebo group.
3.1.4. Fecal odor
The respective amount of change in VAS questionnaire scores
regarding fecal odor from before starting ingestion to after 2 weeks
of ingestion and from before starting ingestion to after 4 weeks of
ingestion was as follows: placebo group, 12.95 ± 19.35 mm and
21.63 ± 23.03 mm; 50 mg/day group, 11.22 ± 15.34 mm and
15.56 ± 19.57 mm; 500 mg/day group, 19.26 ± 14.30 mm and
27.10 ± 21.27 mm; 1000 mg/day group, 18.95 ± 21.98 mm and
30.95 ± 22.14 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, fecal odor
signiﬁcantly improved after 2 and 4 weeks of ingestion compared
with that before starting ingestion (p ¼ 0.001, p ¼ 0.001). After 2
and 4 weeks of ingestion, differences were also observed between
all ingestion groups and the placebo group.
3.1.5. Bowel movement regularity
The respective amount of change in VAS questionnaire scores
regarding bowel movement regularity from before starting inges-
tion to after 2 weeks of ingestion and from before starting ingestion
to after 4 weeks of ingestion was as follows: placebo group,
3.26 ± 14.67 mm and 8.74 ± 19.38 mm; 50 mg/day
group, 1.76 ± 21.60 mm and 6.89 ± 13.42 mm; 500 mg/day group,
5.00 ± 16.06 mm and 1.85 ± 11.80 mm; 1000 mg/day
group, 8.22 ± 21.51 mm and 8.82 ± 30.52 mm. When test
multiplicity was adjusted and the level of signiﬁcance for each test
was set at 2.5%, no signiﬁcant differences were observed between
values at the day of starting ingestion and at each measurement
time point.
3.1.6. Strain during bowel movements
The respective amount of change in VAS questionnaire scores
regarding strain during bowel movements from before starting
ingestion to after 2 weeks of ingestion and from before starting
ingestion to after 4 weeks of ingestion was as follows: placebo
group, 5.79 ± 30.44 mm and 0.16 ± 17.05 mm; 50 mg/day group,
6.11 ± 32.04 mm and 11.61 ± 16.99 mm; 500 mg/day group,0.70 ± 13.19 mm and 3.70 ± 11.62 mm; 1000 mg/day group,
8.68 ± 11.89 mm and 5.89 ± 27.58 mm. When test multiplicity was
adjusted and the level of signiﬁcance for each test was set at 2.5%,
strain during bowel movements signiﬁcantly decreased after 2
weeks of ingestion compared with that before starting ingestion
(p ¼ 0.005).
3.1.7. Sensation of residual stools
The respective amount of change in VAS questionnaire scores
regarding sensation of residual stools frombefore starting ingestion
to after 2 weeks of ingestion and from before starting ingestion to
after 4 weeks of ingestion was as follows: placebo
group: 2.21 ± 15.37 mm and 2.00 ± 13.59 mm; 50 mg/day group,
5.89 ± 19.58 mm and 2.94 ± 14.74 mm; 500 mg/day group,
1.45 ± 14.25 mm and 0.45 ± 21.81 mm; 1000 mg/day group,
6.74 ± 13.01 mm and 2.78 ± 24.18 mm. When test multiplicity was
adjusted and the level of signiﬁcance for each test was set at 2.5%,
no signiﬁcant differences were observed between values at the day
of starting ingestion and at each measurement time point.
3.2. VAS questionnaire for the cooperating people
We implemented a VAS questionnaire regarding odor for
cooperating people as well. It comprised the four items of subject
halitosis, pillow odor, pajama odor, and fecal odor (odor of feces
after subject used the toilet). We then calculated the amount of
change in mean scores and standard deviation for each group for
each measurement time point (evaluation time point) from before
starting ingestion (Table 5). With regard to the amount of change,
we also calculated frequency distribution after dividing subjects
into ﬁve levels (<20, 20e39, 40e59, 60e79, and 80 years). The
results for each of these four items are shown below.
3.2.1. Halitosis
The respective amount of change in VAS questionnaire scores
regarding halitosis from before starting ingestion to after 2 weeks
of ingestion and from before starting ingestion to after 4 weeks of
ingestion was as follows: placebo group, 6.58 ± 20.46 mm and
11.58 ± 22.47 mm; 50 mg/day group, 0.53 ± 26.42 mm and
6.94 ± 27.92 mm; 500 mg/day group, 12.50 ± 33.37 mm and
19.75 ± 17.54 mm; 1000 mg/day group, 11.05 ± 27.97 mm and
21.53 ± 29.79 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, halitosis signiﬁ-
cantly improved after 2 weeks of ingestion compared with that
before starting ingestion (p ¼ 0.005). After 2 weeks of ingestion,
differences were also observed in the 50 and 500 mg/day ingestion
groups compared with the placebo group. After 4 weeks of inges-
tion, differences were observed in all ingestion groups compared
with the placebo group.
3.2.2. Pillow odor
The respective amount of change in VAS questionnaire scores
regarding pillow odor from before starting ingestion to after 2
weeks of ingestion and from before starting ingestion to after 4
weeks of ingestion was as follows: placebo group, 5.95 ± 14.05 mm
and 8.63 ± 20.35 mm; 50 mg/day group, 10.81 ± 22.81 mm and
Table 4
VAS questionnaire for subjects on odor.
Halitosis Pillow odor Pajama odor Fecal odor
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Before ingestion After 2 weeks
of ingestion
After 4 weeks
of ingestion
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Placebo group 52.53 ± 24.74 63.47 ± 23.72a 71.63 ± 18.64a 61.88 ± 20.32 72.32 ± 17.39 75.05 ± 16.00 66.95 ± 21.57 72.00 ± 17.07 76.32 ± 16.75 47.53 ± 26.75 60.47 ± 21.59a 69.16 ± 18.79
Amount of change 10.95 ± 16.99 19.11 ± 18.89 9.00 ± 18.10 10.82 ± 22.36 5.05 ± 11.13 9.37 ± 17.36 12.95 ± 19.35 21.63 ± 23.03
50 mg/day champignon
ingestion group
48.39 ± 25.60 67.72 ± 21.87a 70.83 ± 18.55a 61.06 ± 24.90 72.17 ± 19.45a 73.17 ± 20.62a 64.44 ± 24.15 72.50 ± 20.07a 71.44 ± 22.16 47.72 ± 17.91 58.94 ± 22.14a 63.28 ± 20.76a
Amount of change 19.33 ± 20.40c 22.44 ± 22.59 11.11 ± 10.53c 12.11 ± 17.78c 8.06 ± 13.33c 7.00 ± 17.23 11.22 ± 15.34c 15.56 ± 19.57c
500 mg/day
champignon
ingestion group
46.30 ± 15.26 60.05 ± 16.66a 64.15 ± 18.15a 53.75 ± 23.19 72.80 ± 17.33a 74.85 ± 17.24a 53.20 ± 23.44 73.95 ± 16.04a 74.90 ± 18.67a 38.35 ± 13.43 58.16 ± 15.43a 65.45 ± 18.60a
Amount of change 13.75 ± 17.59c 17.85 ± 20.78c 19.05 ± 22.02c 21.10 ± 26.00c 20.75 ± 22.19c 21.70 ± 28.25c 19.26 ± 14.30c 27.10 ± 21.27c
1000 mg/day
champignon
ingestion group
44.79 ± 20.44 62.40 ± 19.43a 71.95 ± 16.46a 62.65 ± 25.84 74.85 ± 16.53a 80.15 ± 12.09a 64.85 ± 23.03 77.00 ± 16.06a 79.85 ± 12.18a 37.63 ± 22.27 56.55 ± 21.41a 69.30 ± 14.44a
Amount of change 20.00 ± 19.22c 29.32 ± 25.56c 12.20 ± 16.47c 17.50 ± 22.99 12.15 ± 17.33c 15.00 ± 20.48c 18.95 ± 21.98c 30.95 ± 22.14c
bStatistically signﬁcant compared with the placebo (p < 0.05,ManneWhitney).
a Statistically signifcant vs before taking test foods or placebo (p < 0.05,Wilcoxon).
c Statistically signﬁcant compared with the placebo (p < 0.05,Chi-square).
Table 5
VAS questionnaire for the cooperating people on odor.
Halitosis Pillow odor Pajama odor Fecal odor
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Before
ingestion
After 2 weeks
of ingestion
After 4 weeks
of ingestion
Placebo group 60.37 ± 27.66 66.95 ± 23.92 71.89 ± 15.93 62.32 ± 27.66 68.16 ± 24.17 70.89 ± 18.16 64.11 ± 28.12 69.53 ± 21.90 74.89 ± 17.14a 47.37 ± 24.70 54.47 ± 21.71 62.32 ± 19.14a
Amount of change 6.58 ± 20.46 11.58 ± 22.47 5.95 ± 14.05 8.63 ± 20.35 5.53 ± 15.07 10.89 ± 17.72 7.37 ± 21.68 15.05 ± 21.65
50 mg/day champignon
ingestion group
66.41 ± 29.40 65.82 ± 27.40 73.29 ± 21.14 59.75 ± 25.35 70.63 ± 28.53 70.00 ± 30.84 64.13 ± 26.08 71.06 ± 28.90 74.94 ± 29.54 49.47 ± 22.33 59.94 ± 30.47 67.12 ± 25.67a
Amount of change 0.53 ± 26.42c 6.94 ± 27.92c 10.81 ± 22.81 14.63 ± 26.08c 6.94 ± 23.10c 10.81 ± 24.68c 10.35 ± 26.97 17.59 ± 28.05c
500 mg/day champignon
ingestion group
44.70 ± 26.07 56.95 ± 22.95 64.50 ± 24.24a 47.05 ± 24.62 62.35 ± 23.55a 64.55 ± 25.79a 49.75 ± 25.05 62.90 ± 22.80a 69.90 ± 22.94a 33.25 ± 18.56 49.60 ± 19.45a 56.55 ± 21.78a
Amount of change 12.50 ± 33.37c 19.75 ± 17.54c 15.45 ± 21.85c 17.50 ± 22.81c 13.20 ± 19.26 20.15 ± 22.00c 16.40 ± 17.97 23.30 ± 18.50c
1000 mg/day champignon
ingestion group
54.26 ± 26.64 65.21 ± 20.41 75.79 ± 18.23a 56.00 ± 26.44 70.32 ± 16.34a 77.16 ± 15.67a 58.74 ± 27.00 72.58 ± 19.09a 78.79 ± 15.60a 44.79 ± 23.07 60.79 ± 17.05a 70.26 ± 19.99a
Amount of change 11.05 ± 27.97 21.53 ± 29.79c 14.16 ± 21.88c 21.11 ± 27.06c 13.89 ± 23.25c 20.05 ± 30.24c 16.11 ± 27.49c 25.58 ± 24.49c
bStatistically signﬁcant compared with the placebo (p < 0.05,ManneWhitney).
a Statistically signifcant vs before taking test foods or placebo (p < 0.05,Wilcoxon).
c Statistically signﬁcant compared with the placebo (p < 0.05,Chi-square).
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17.50 ± 22.81 mm; 1000 mg/day group, 14.16 ± 21.88 mm and
21.11 ± 27.06 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, body odor
signiﬁcantly improved after 2 and 4 weeks of ingestion compared
with that before starting ingestion (p ¼ 0.011, p ¼ 0.003). After 2
weeks of ingestion, differences were also observed in the 500 and
1000 mg/day ingestion groups compared with the placebo group.
After 4 weeks of ingestion, differences were observed in all inges-
tion groups compared with the placebo group.3.2.3. Pajama odor
The respective amount of change in VAS questionnaire scores
regarding pajama odor from before starting ingestion to after 2
weeks of ingestion and from before starting ingestion to after 4
weeks of ingestion was as follows: placebo group, 5.53 ± 15.07 mm
and 10.89 ± 17.72 mm; 50 mg/day group, 6.94 ± 23.10 mm and
10.81 ± 24.68 mm; 500 mg/day group, 13.20 ± 19.26 mm and
20.15 ± 22.00 mm; 1000 mg/day group, 13.89 ± 23.25 mm and
20.05 ± 30.24 mm. When test multiplicity was adjusted and the
level of signiﬁcance for each test was set at 2.5%, pajama odor
signiﬁcantly improved after 2 and 4 weeks of ingestion compared
with that before starting ingestion (p ¼ 0.018, p ¼ 0.010). After 2
weeks of ingestion, differences were also observed in the 500 and
1000 mg/day ingestion groups compared with the placebo group.
After 4 weeks of ingestion, differences were observed in all inges-
tion groups compared with the placebo group.3.2.4. Fecal odor (odor after using toilet)
The respective amount of change in VAS questionnaire scores
regarding fecal odor (odor after using toilet) from before starting
ingestion to after 2 weeks of ingestion and from before starting
ingestion to after 4 weeks of ingestion was as follows: placebo
group, 7.37 ± 21.68 mm and 15.05 ± 21.65 mm; 50 mg/day group,
10.35 ± 26.97 mm and 17.59 ± 28.05 mm; 500 mg/day group,
16.40 ± 17.97 mm and 23.30 ± 18.50 mm; 1000 mg/day group,
16.11 ± 27.49 mm and 25.58 ± 24.49 mm. When test multiplicity
was adjusted and the level of signiﬁcance for each test was set at
2.5%, fecal odor signiﬁcantly improved after 2 and 4 weeks of
ingestion compared with that before starting ingestion (p ¼ 0.021,
p ¼ 0.001). After 2 weeks of ingestion, differences were also
observed only in the 1000 mg/day ingestion groups compared with
the placebo group. After 4 weeks of ingestion, differences were
observed in all ingestion groups compared with the placebo group.3.3. Bowel movement journal
Subjects in the three ingestion groups recorded in diaries in-
formation regarding bowelmovement frequency, bowel movement
regularity, bowel movement volume, stool shape, stool color, stool
odor, and sensation of having completely evacuated after each
bowel movement.3.3.1. Results for the 50 and 500 mg/day groups vs. placebo group
When testmultiplicity was adjusted and the level of signiﬁcance
for each test was set at 5/3 (¼1.67%) for the 50 mg/day group and
placebo group, the proportion of responses indicating that stool
color was “brown, ocher, or yellow” was signiﬁcantly higher in the
placebo group on the day of starting ingestion and after 4 weeks of
ingestion (p ¼ 0.002, p ¼ 0.001). No signiﬁcant differences were
noted for any evaluation items between the 500 mg/day group and
placebo group.3.3.2. Results for the 1000 mg/day group vs. placebo group
The following results clearly suggested the superiority of the
test food when the 1000 mg/day group and placebo group were
compared. First, when test multiplicity was adjusted and the level
of signiﬁcance for each test was set at 2.5% for bowel movement
frequency, the amount of change in bowel movement frequency
from before starting ingestion to after 2 and 4 weeks of ingestion
was signiﬁcantly higher in the ingestion groups (p ¼ 0.016,
p ¼ 0.006). When test multiplicity was adjusted and the level of
signiﬁcance for each test was set at 5/2¼ 2.5% for bowel movement
volume, the amount of change in bowel movement volume from
before starting ingestion to after 4 weeks of ingestion was signiﬁ-
cantly higher in the ingestion group (1000 mg/day) than in the
placebo group (p ¼ 0.014).
When testmultiplicity was adjusted and the level of signiﬁcance
for each test was set at 5/3 (¼1.67%) for stool color, the proportion
of responses indicating “brown, ocher, or yellow” was signiﬁcantly
higher in the placebo group after 4 weeks of ingestion (p ¼ 0.001).
When testmultiplicity was adjusted and the level of signiﬁcance for
each test was set at 5/3 (¼1.67%) for sensation of having completely
evacuated after each bowel movement, the proportion of responses
indicating “smooth or pleasantly smoothwas signiﬁcantly higher in
the all ingestion group after 2 weeks of ingestion (p ¼ 0.001).
3.4. Food frequency questionnaire (glycometabolism-related items)
We conducted a survey using the food frequency questionnaire
to conﬁrm that there was no bias related to food ingestion during
the trial. No signiﬁcant differences related to caloric intake, car-
bohydrates, protein, fat, dietary ﬁber, or salt were observed. We
also did not observe any signiﬁcant differences with regards to
blood sugar or HbA1c levels during fasting.
4. Discussion
Champignon mushrooms, which have originated from Europe
and North America, are currently grown in over 70 countries
worldwide. They are the most widely eaten of mushroom variety
and are known to havemany beneﬁcial nutritional properties. First,
they contain large amounts of vitamin D and ergosterol, which are
important for bone metabolism. Therefore, they are effective for
preventing onset and improving symptoms of osteoporosis.3,4 They
are also rich in minerals such as sodium, calcium, and phosphorus
and contain linoleic acid and antioxidants, which have been asso-
ciated with prevention of arteriosclerosis.5,6 The foaming compo-
nents of champignon mushrooms show aromatase-inhibiting7,8
and anticarcinogenic9,10 effects and can activate natural killer
cells, thus promoting the innate immune system.11 In vitro studies
have also reported that champignonmushrooms promote dendritic
cell function.12 Moreover, they show anti-inﬂammatory proper-
ties13 and have been suggested to inhibit inﬂammation and cancer
cell proliferation through macrophages.14 Notably, because they
inhibit the development of fatty liver,15 champignon mushrooms
can possibly prevent lifestyle-related diseases.
In the present placebo-controlled double-blind parallel-group
comparative study targeting 80 men and women aged 50e79
years with problematic halitosis and body and fecal odor, the effects
of 4-week daily ingestion of 50, 500, and 1000 mg/day champignon
extract on the aforementioned conditions were investigated. Our
results demonstrated the efﬁcacy of champignon extract. We also
conducted a questionnaire survey regarding bowel movements and
found that champignon extract also exhibited bowel movement-
related effects. Moreover, no marked differences were observed
between the placebo group and all ingestion groups with regard to
vital signs, blood test ﬁndings, liver function, kidney function, lipid
J. Nishihira et al. / Journal of Traditional and Complementary Medicine 7 (2017) 110e116116proﬁle, blood glucose levels, or physical measurement during the
ingestion of low, medium, or high doses of champignon extract
(data not shown). Furthermore, because most ﬁndings were within
the normal range, this trial was considered safe.
The following conclusions were drawn from the results of the
VAS questionnaire regarding halitosis and body and fecal odor. For
each of the champignon extract ingestion groups, improvement or
improvement tendencies were observed for halitosis and body and
fecal odor compared with the placebo group, even in case of
cooperating people's data.
Considering the bowel movement journals, for the 50 mg/day
ingestion and placebo groups, the proportion of responses indi-
cating that stool color was “brown, ocher, or yellow” was signiﬁ-
cantly higher in the placebo group after 2 and 4 weeks of ingestion.
Bowel movement volume signiﬁcantly improved in the 1000mg/
day group after 4 weeks of ingestion. For sensation of having
completely evacuated after each bowel movement, there was a
signiﬁcantly high proportion of responses indicating “cleared out or
veryclearedout” in the1000mg/daygroupafter2weeksof ingestion.
These results demonstrate that although no clear improvement
was observed in bowel movements with 50 mg/day champignon
extract ingestion, whereas they clearly improved with a 500 mg/
day ingestion. In particular, results showed that bowel movement
improvement could be anticipated by the ingestion of a high dose
of champignon extract. Our results strongly suggest that the
ingestion of 50e1000 mg/day of our test food may improve hali-
tosis and body and fecal odor. In particular, ingestion of the high
dose of 1000 mg/day may result in reduction in the odor and
favorable intestinal tract environment.
Conducting component analysis of champignon extract to iden-
tify the main components causing the deodorizing effects and
determining the optimal dosage and other variables in detail is
necessary. VAS questionnaire regarding bowel movements also
showed that ingestion of a high dose of champignon extract showed
clear improvements. Thus, efﬁcacy in a wide range of areas, from
body odor to bowel movements, can be anticipated. Although the
safety of champignon mushrooms has been highly reported, there
have been no reports on their adverse or toxic effects in humans.16
Kareishu appears with increasing age, but its incidence is
increasing in Japan as a result of the higher animal fat intake
through increasingly westernized diets as well as increase social
stress. Halitosis and body and fecal odor not only decrease a per-
son's quality of life but also can become serious problems in care-
giving settings in Japan because the proportion of the elderly
population in Japanese society is rapidly increasing.
In conclusion, champignon extract is efﬁcacious against halitosis
and body and fecal odor, and it can also improve the intestinal
environment. These ﬁndings not only provide extremely helpful
data that can contribute to the maintenance and improvement ofhealth of the people of Japan but also encourage further develop-
ment of champignon extract as a dietary supplement.5. Conclusion
Champignon extract is efﬁcacious against halitosis and body and
fecal odor, and it can also improve the intestinal environment.
These ﬁndings not only provide extremely helpful data that can
contribute to the maintenance and improvement of health of the
people of Japan but also encourage further development of cham-
pignon extract as a dietary supplement.References
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